The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be
a) a guide for reporting for authors of RCTs,
b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.
Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.
In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).
Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the...
caption:
Eysenbach G, CONSORT-EHEALTH Group
CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions
J Med Internet Res 2011;13(4):e126
URL: http://www.jmir.org/2011/4/e126/
doi: 10.2196/jmir.1923
PMID: 22209829

Your name *
First Last
Yolanda Morcillo-Muñoz

Primary Affiliation (short), City, Country *
University of Toronto, Toronto, Canada
Primary Care, Andalusian Health Service Distri

Your e-mail address *
abc@gmail.com
ymmcadiz1969@gmail.com
Title of your manuscript *
Provide the (draft) title of your manuscript.

Multimodal Chronic Pain Therapy for Adults Via Smartphones:
A Randomized Controlled Clinical Trial

Name of your App/Software/Intervention *
If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

NO + Dolor (NO + Pain). Which contains an Anc

Evaluated Version (if any)
e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

Release 2019-05-01. Version 2.1.12

Language(s) *
What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

Spanish, (prepared for english)
URL of your Intervention Website or App

e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

https://apps.apple.com/es/app/no-más-dolor-edcno/id1458096026

URL of an image/screenshot (optional)

Tu respuesta

Debe ser una URL válida

Accessibility *

Can an enduser access the intervention presently?

- access is free and open
- access only for special usergroups, not open
- access is open to everyone, but requires payment/subscription/in-app purchases
- app/intervention no longer accessible
- Otro:

Primary Medical Indication/Disease/Condition *

e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

"Pain " "Adults with chronic pain"
Primary Outcomes measured in trial *
comma-separated list of primary outcomes reported in the trial

Catastrophizing, helplessness, rumination, magnification

Secondary/other outcomes
Are there any other outcomes the intervention is expected to affect?

Pain acceptance, health-related quality of life, pain, anxiety, depression, mobility, personal care, everyday activities

Recommended "Dose" *
What do the instructions for users say on how often the app should be used?

- [ ] Approximately Daily
- [x] Approximately Weekly
- [ ] Approximately Monthly
- [ ] Approximately Yearly
- [ ] "as needed"
- [ ] Otro:

https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_Oim...=en_US&formkey=dGIKd2Z2Q1NSGQ0THltazM5MS1aWWc6MA&rm=full
Approx. Percentage of Users (starters) still using the app as recommended after 3 months *

- unknown / not evaluated
- 0-10%
- 11-20%
- 21-30%
- 31-40%
- 41-50%
- 51-60%
- 61-70%
- 71%-80%
- 81-90%
- 91-100%
- Otro:
Overall, was the app/intervention effective? *

- yes: all primary outcomes were significantly better in intervention group vs control
- partly: SOME primary outcomes were significantly better in intervention group vs control
- no statistically significant difference between control and intervention
- potentially harmful: control was significantly better than intervention in one or more outcomes
- inconclusive: more research is needed
- Otro:

Article Preparation Status/Stage *
At which stage in your article preparation are you currently (at the time you fill in this form)

- not submitted yet - in early draft status
- not submitted yet - in late draft status, just before submission
- submitted to a journal but not reviewed yet
- submitted to a journal and after receiving initial reviewer comments
- submitted to a journal and accepted, but not published yet
- published
- Otro:
Journal *
If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under “other”)

- not submitted yet / unclear where I will submit this
- Journal of Medical Internet Research (JMIR)
- JMIR mHealth and UHealth
- JMIR Serious Games
- JMIR Mental Health
- JMIR Public Health
- JMIR Formative Research
- Other JMIR sister journal
- Otro:

Is this a full powered effectiveness trial or a pilot/feasibility trial? *

- Pilot/feasibility
- Fully powered
Manuscript tracking number *

If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

- no ms number (yet) / not (yet) submitted to / published in JMIR
- Otro: JMIR ms#36114

TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? *

I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")

- yes
- Otro:
1a-i) Identify the mode of delivery in the title

Identify the mode of delivery. Preferably use “web-based” and/or “mobile” and/or “electronic game” in the title. Avoid ambiguous terms like “online”, “virtual”, “interactive”. Use “Internet-based” only if Intervention includes non-web-based Internet components (e.g. email), use “computer-based” or “electronic” only if offline products are used. Use “virtual” only in the context of “virtual reality” (3-D worlds). Use “online” only in the context of “online support groups”. Complement or substitute product names with broader terms for the class of products (such as “mobile” or “smart phone” instead of “iphone”), especially if the application runs on different platforms.

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ □ essential

Does your paper address subitem 1a-i? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, “smart-phone” is included in the title

1a-ii) Non-web-based components or important co-interventions in title

Mention non-web-based components or important co-interventions in title, if any (e.g., “with telephone support”).

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ □ essential

Borrar selección
Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. "with telephone support”

1a-iii) Primary condition or target group in the title

Mention primary condition or target group in the title, if any (e.g., “for children with Type I Diabetes”) Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

Does your paper address subitem 1a-iii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes "Chronic Pain Adults" is the target patient population, and is included in the title.

1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.
1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all important  ○  ○  ○  ○  ● essential

Borrar selección

Does your paper address subitem 1b-i? *

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. See ABSTRACT in ms for further information. “fully automated”. The intervention group received a standard, (video, audio, text) psychosocial therapy-type program of activities through a smartphone for 6 weeks. The control group only had access to the “Find out more” section of the application, which contains audiovisual material for pain management based on a self-help approach.

Comparator: “publicly available websites”
1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like “fully automated” vs. “therapist/nurse/care provider/physician-assisted” (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1  2  3  4  5

subitem not at all important ○ ○ ○ ○ ☑  essential

Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. “Psychosocial therapy-type program through a smartphone”. “Find out more” section of the application, which contains audiovisual material for pain management based on a self-help approach.
1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed user group trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use “blinded” or “unblinded” to indicated the level of blinding instead of “open”, as “open” in web-based trials usually refers to “open access” (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. “Most outcome data are collected online.”; “Blinding is implemented during data analysis and in patient recruitment”

1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)
Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. Results section in the abstract reports the number of participants who took part in the study as well as study outcomes (with reported significance "p") (for further information see ABSTRACT in ms).

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. Conclusion for the abstract reports outcome of study: (for further information see ABSTRACT in ms).

INTRODUCTION
2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in “Methods” under 5)

1 2 3 4 5
subitem not at all important 0 0 0 0 0 essential

Borrar selección

Does your paper address subitem 2a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. Is Intended incorporated in broader health care program, intended for patient pain chronic and the use smartphone-based applications complement other solutions.

2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropriate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

1 2 3 4 5
subitem not at all important 0 0 0 0 0 essential

Borrar selección
Does your paper address subitem 2a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. "There is a large body of research on multi-disciplinary treatment programs for adults with chronic pain that has reviewed the clinical evidence and effectiveness of treatments for pain, as well as the cost-effectiveness of these programs in outpatient settings". (for further information see INTRODUCTION in ms).

2b) In INTRODUCTION: Specific objectives or hypotheses

Does your paper address CONSORT subitem 2b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. Hypotheses and objectives are mentioned

METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio
Does your paper address CONSORT subitem 3a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. "A randomized controlled clinical trial was performed using parallel treatment groups". The allocation ratio is stated in the RANDOMIZATION AND ALLOCATION section. "Block randomization was used to ensure similar numbers of subjects in each group and intervention phase (Fig. 1). Assessed for eligibility (n=297). Randomized (n=209) Received allocated intervention (n=98) and control (n=96)."

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

There were no changes to the methodology after the trial commenced.

3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

1 2 3 4 5
subitem not at all important 0 1 0 0 0 essential
Borrar selección
Does your paper address subitem 3b-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no 'bugs, downtimes or content changes' that influence study design.

4a) Eligibility criteria for participants

Does your paper address CONSORT subitem 4a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes."Patients ≥ 18 years of age with pain of any location". "Pain with a duration of ≥3 months". "Pain with an intensity of ≥4 on the Visual Numerical Scale (VNS)". "Presenting one of the following characteristics: continuous pain, intermittent pain ≥5 days a week". "Able to use a smartphone". "Not participating in another research project".

4a-i) Computer / Internet literacy
Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

1 2 3 4 5

subitem not at all important ○ ○ ● ○ ○ essential

Borrar selección
Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

The participants used COMPUTER to send the questionnaires via email. Participants did not use a computer or the internet for others aspect of this study.

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

1 2 3 4 5

subitem not at all important ○ ○ ○ ● ○ essential

Borrar selección
Does your paper address subitem 4a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes."We explain in the Randomization and Blinding and Treatment Procedures, this intervention is "fully-automated" Block randomization with a block size of 4 was used. The only stratification criterion was the reference health center of the patient in question. An automated recruitment form hosted on the REDCap platform of the Maimonides Biomedical Research Institute of Cordoba (IMIBIC) was used to randomize the patients by simply clicking a button. The data were transferred and recorded in an electronic notebook using the Data Entry Manager (CDR) system. The statistician, the principal investigator and the co-investigators of the study who evaluated the results were not involved in patient recruitment and were blinded to group assignment. The twenty-two recruiters from the 11 primary care health centers of the Cordoba South Health District in 2019 who recruited the patients in 2019 were also responsible for randomizing the patients (i.e., clicking the button on the automated recruitment form) and were not blinded"

4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

1 2 3 4 5

subitem not at all important essential
Does your paper address subitem 4a-iii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. (for further information see PARTICIPANTS under Methods in ms).

4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes."A between-subjects experimental study was conducted at the 11 primary care health centers of the Cordoba South Health District "

4b-i) Report if outcomes were (self-)assessed through online questionnaires
Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.

subitem not at all important

1 2 3 4 5

essential
Does your paper address subitem 4b-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. We explain in the PROCEDURES section that to assess the treatments, self-reported questionnaires were sent to the participants by email and collected at three time points: at admission to the program (T1), at week six of the intervention (T2) and three months after the intervention (T3). The participants completed all three questionnaires at home and returned them by email.

4b-ii) Report how institutional affiliations are displayed
Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention. (Not a required item – describe only if this may bias results)

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential

Borrar selección

Does your paper address subitem 4b-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Affiliations were clearly displayed to participants in participant information sheet (for further information see under Methods in ms).

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered
5-i) Mention names, credential, affiliations of the developers, sponsors, and owners
Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a “Conflict of interest” section or mentioned elsewhere in the manuscript).

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 5-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. See ACKNOWLEDGEMENTS at the end of the ms for further information.

5-ii) Describe the history/development process
Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ ○ essential
Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. “To develop the contents of the multimodal treatment for the mobile device application (app), a systematized literature review was carried out in a first phase following the Scottish Intercollegiate Guideline Network (SIGN) guidelines. The second part of our study consisted in the prioritization of self-management recommendations for chronic pain selected from the reviewed literature using a participatory approach. Specifically, we designed a multimodal intervention protocol combining physical exercise, psychoeducational therapy, health assets and pharmacological treatment, which was delivered using a mobile device. The effectiveness of the intervention was subsequently evaluated by means of a clinical trial [39].

5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was “frozen” during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

There were no revisions or updating the study methodology during in evaluation process.
5-iv) Quality assurance methods

Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.

subitem not at all important 〇 〇 〇 〇 〇 essential

Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The research methodology and monitoring of data collection overseen by the principal investigator (PI) Yolanda Morcillo. All condition checked at baseline and half way point by Dr Antonio Jose Sanchez Guarnido.

5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used

Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

subitem not at all important 〇 〇 〇 〇 〇 essential
Does your paper address subitem 5-v?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. Methodology of the experiment clearly explained (for further information see EXPERIMENTAL DESIGN and PROCEDURE under Methods in ms).

5-vi) Digital preservation
Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, webcitation.org, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

subitem not at all important  ○  ○  ☐  ○  ○  essential

Borrar selección

Does your paper address subitem 5-vi?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

(https://apps.apple.com/es/app/no-más-dolor-edcno/id1458096026).
### 5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained “access to the platform and Internet” [1]. To ensure access for editors/reviewers/readers, consider to provide a “backdoor” login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| **subitem not at all important** | | | | ☐ | ☐ | essential |

Borrar selección

---

**Does your paper address subitem 5-vii?** *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. Access to the intervention is presented in the PROCEDURES section: "At the group meeting, the patients who agreed to participate voluntarily in the study were informed that they would receive instructions by email on how to download the mobile application with the contents of the treatment. The patients were also informed that if they were selected to participate in the intervention group, the treatment would last from 6 to 8 weeks. The control group would only have access to the “Find out more” section of the application, which contains audiovisual materials for pain management from a self-help approach, such as information on the origin of chronic pain and advice for pain treatment and relaxation".
5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1], whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback” [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

Does your paper address subitem 5-viii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. The intervention consisted of the implementation of a "program of standard", psychosocial therapy activities. The pain management application enables "automatic monitoring, skills training, social support, education, goal setting, and the achievement of four components: psychological wellness, exercise, pharmacological treatment and health assets." Each week, the participants received three activities for each of the above components via the "NO + pain" app until completing the six weeks of treatment. All the activities are designed to be done weekly except for the walking challenge, which is done daily. The first time a participant completes an activity, they are awarded a star. Participants can do the proposed activity as many times as they like but no more rewards are given until the following week. The more activities they complete, the more stars they are awarded and the higher the percentage of goals reached by the patients each week "(Appendix 1)". The application also has a "Consultation" section with a contact form where the participants can send any questions or comments. The form is then sent by email to the researchers so that they can respond to the inquiries.
5-ix) Describe use parameters

Describe use parameters (e.g., intended “doses” and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

1 2 3 4 5

subitem not at all important  ○ ○ ○ ○ ○ essential

Borrar selección

Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. The intervention group received the treatment via their smartphones (APP No+PAIN) for a period of six weeks after completing the two face-to-face sessions. Appendix1. Key contents to complete the intervention. (for further information see PROCEDURES under Methods in ms).

5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as “type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered”. It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

1 2 3 4 5

subitem not at all important  ○ ○ ○ ○ ○ essential

Borrar selección
Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. Experiment involved an interaction between and human participant and a App. A human researcher was present to provide instruction, administer measures and answer questions. We state that the intervention is fully-automated.

5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

1 2 3 4 5

subitem not at all important ○ ○ ○ ● ○ essential

Borrar selección

Does your paper address subitem 5-xi? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No prompts reminders were used in this study.
5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential

Borrar selección

Does your paper address subitem 5-xii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No co-interventions were used for this study.

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed
Does your paper address CONSORT subitem 6a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. **Primary Outcome: Catastrophizing**

The descriptive results for differences between the control and intervention groups regarding measures of catastrophizing at baseline, upon completion of the treatment and during follow-up are presented in Table 2. Between-group variations over time for the primary outcome variable are presented in Table 3. The Spanish adaptation\[49,50\] of the Pain Catastrophizing Scale (PCS)[51] was used to measure the main outcome variable of the study[52].

"Secondary Outcomes" Table 5 shows the results for the variables acceptance (CPAQ), quality of life (EQ-5D) and overall health state (EQ-VAS), while Table 6 shows variations over time for the secondary outcomes. The Spanish adaptation[53] of the Chronic Pain Acceptance Questionnaire (CPAQ) was used[22] to measure engagement in life activities despite pain; the willingness to experience pain without trying to control, change or avoid it; the ability to recognize the chronicity of pain and the need to avoid or control pain. The Spanish adaptation of the EQ-5D [54], was used to measure health-related quality of life (HRQoL). This version can be used both in relatively healthy individuals (general population) and in groups of patients with different conditions.

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

1 2 3 4 5

| subitem not at all important | essential |
|------------------------------|-----------|
| ○                            | ○         |
Does your paper address subitem 6a-i?

Copy and paste relevant sections from manuscript text

N/A

Your answer must have a minimum of 25 characters.

6a-ii) Describe whether and how “use” (including intensity of use/dosage) was defined/measured/monitored

Describe whether and how “use” (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

1 2 3 4 5

subitem not at all important ○ ○ ● ○ ○ essential

Does your paper address subitem 6a-ii?

Copy and paste relevant sections from manuscript text

N/A

Your answer must have a minimum of 25 characters.
6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained

Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).

1  2  3  4  5

subitem not at all important  ○  ○  ○  ○  ○  essential

Does your paper address subitem 6a-iii?
Yes. The application also has a “Consultation” section with a contact form where the participants can send any questions or comments. The form is then sent by email to the researchers so that they can respond to the inquiries.

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? *
No changes were made to the trial after commencement
7a) How sample size was determined
NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size
Describe whether and how expected attrition was taken into account when calculating the sample size.

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important | ○ | ○ | ○ | ● | ○ |

Does your paper address subitem 7a-i?
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes.." Accepting an alpha error of 0.05 and a beta error of 0.2 (statistical power of 80%) in a two-tailed test and estimating 15% loss to follow-up, n = 296 is required to detect a statistically significant difference between two means at 3 points in our outcome variable with an estimated standard deviation of 12".
To obtain different trajectories for each group (experimental vs. control) over time, we included the "intercept and slope effect as random effects"; and "time, group and the interaction term (group × time) as fixed effects". The "variance-covariance" structure was fixed to an unstructured matrix and the random effects and error terms were assumed to have a normal distribution. Furthermore, "Cohen's d" was calculated based on the results of the "linear mixed model" (Cohen, 1988). The established level of statistical significance was P < .05."
7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No interim analyses or stopping guidelines were applicable to this study.

8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Block randomization with a block size of 4 was used. The only stratification criterion was the reference health center of the patient in question. An automated recruitment form hosted on the REDCap platform of the Maimonides Biomedical Research Institute of Cordoba (IMIBIC) was used to randomize the patients by simply clicking a button. The data were transferred and recorded in an electronic notebook using the Data Entry Manager (CDR) system. The statistician, the principal investigator and the co-investigators of the study who evaluated the results were not involved in patient recruitment and were blinded to group assignment.

8b) Type of randomisation; details of any restriction (such as blocking and block size)
9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The assignment sent by the coordinating center in electronic list (.xls) format was uploaded in the RED CAP platform. The allocation sequence is concealed. Upon submission of the baseline questionnaire, the RED CAP platform sends an automated email of the assignment to the participant. This email includes the hyperlink and password to access the experimental app NO+PAIN, or to receive a different hyperlink to access the control of publicly available websites."

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions
Does your paper address CONSORT subitem 10? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. The co-investigators enrolled participants, and who assigned participants to interventions and were not blinded (i.e., clicking the button on the automated recruitment form).

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn’t

Specify who was blinded, and who wasn’t. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important | | | | | essential |
Does your paper address subitem 11a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. The statistician, the principal investigator and the co-investigators of the study who evaluated the results were not involved in patient recruitment and were blinded to group assignment. The twenty-two recruiters from the 11 primary care health centers of the Cordoba South Health District in 2019 who recruited the patients in 2019 were also responsible for randomizing the patients (i.e., clicking the button on the automated recruitment form) and were not blinded. Participants unaware of condition they were randomised to.

11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".

Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Participants were not aware of the differing conditions in the study or which condition they had been assigned too".
11b) If relevant, description of the similarity of interventions
(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The App No+Pain was fully automated " (for further information see PROCEDURES under Methods in ms).

12a) Statistical methods used to compare groups for primary and secondary outcomes
NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

Does your paper address CONSORT subitem 12a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. All statistical methods used are outlined clearly in ms. e.g. "A descriptive analysis was performed for the quantitative variables with mean (M) and standard deviation (SD) and for the qualitative variables with recounts (n) and proportions (%). Goodness-of-fit to a normal distribution was determined using the Shapiro–Wilk test and homogeneity of variance was assessed using Levene's test. ..." (for further information see Data Analysis in ms).
12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

Does your paper address subitem 12a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "In the intervention group, 15 patients did not complete the intervention. The analysis was performed with patients who had completed all three questionnaires at baseline, upon completion of the intervention and three months after the intervention. Table 1 shows the demographic data and baseline characteristics of the sample by groups".

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses
Does your paper address CONSORT subitem 12b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

The descriptive results for differences between the control and intervention groups regarding measures of catastrophizing at baseline, upon completion of the treatment and during follow-up are presented in Table 2. Between-group variations over time for the primary outcome variable are presented in Table 3.

Table 5 shows the results for the variables acceptance (CPAQ), quality of life (EQ-5D) and overall health state (EQ-VAS), while Table 6 shows variations over time for the secondary outcomes.

Table 6 shows the Fisher–Freeman–Halton descriptive analysis of the proportion of participants with clinically significant improvement immediately after treatment according to the EQ-5D subscale.

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

X26-i) Comment on ethics committee approval

|   | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| subitem not at all important | o | o | o | o | essential |
Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. "The study was approved by the Cordoba Research Ethics Committee of the Andalusian Public Health System. Informed consent was approved by the Cordoba Research Ethics Committee and completed by the participants. The study is registered at ClinicalTrial.gov (NCT04509154)."

x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

1 2 3 4 5

subitem not at all important ○ ○ ○ ● ○ essential

Borrar selección
Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. "Written informed consent was obtained immediately prior to the participant undertaking their interaction with the App.

"All patients received a written invitation from their primary care physician or nurse to participate in the study. Two 8-hour face-to-face sessions were held at their reference health center led by one nurse and one primary care physician with experience in the follow-up of chronic pain patients. At the group meeting, the patients who agreed to participate voluntarily in the study were informed that they would receive instructions by email on how to download the mobile application with the contents of the treatment. The patients were also informed that if they were selected to participate in the intervention group, the treatment would last from 6 to 8 weeks. The control group would only have access to the “Find out more” section of the application, which contains audiovisual materials for pain management from a self-help approach, such as information on the origin of chronic pain and advice for pain treatment and relaxation".

X26-iii) Safety and security procedures

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

1 2 3 4 5

subitem not at all important          essential

Borrar selección

https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_Oim...en_US&formkey=dGIKd2Z2Q1INSGQ0THlazM5MS1aWWc6MA&rm=full
RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

Does your paper address CONSORT subitem 13a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Numbers of participants who were randomly assigned".
"Allocated to intervention (n=105), control (n=103). Received intended treatment (n=98), control (n=96), and were analysed for the primary outcome intervention (n=56), control (n=53)".

13b) For each group, losses and exclusions after randomisation, together with reasons
Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes.*A total of 297 subjects (205 females and 92 males) were initially invited to participate in the study. Of these, one was excluded for not meeting the inclusion criteria, 78 because they did not attend the meeting and 20 who declined to participate. A total of 198 subjects (151 women and 47 men) were randomized to one of the two study arms (Fig. 1). After randomization, five subjects were excluded for declining to participate, dropping out before the intervention or because they did not know how to use the technologies. In the intervention group, 15 patients did not complete the intervention.

13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

![Attrition diagram]

Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. Block randomization was used to ensure similar numbers of subjects in each group and intervention phase. Figure 1. Flow chart of recruitment process.
14a) Dates defining the periods of recruitment and follow-up

Does your paper address CONSORT subitem 14a?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. "Recruitment took place in June of 2019".

14a-i) Indicate if critical “secular events” fell into the study period

Indicate if critical “secular events” fell into the study period, e.g., significant changes in Internet resources available or “changes in computer hardware or Internet delivery resources”

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

N/A - no secular events occurred.

14b) Why the trial ended or was stopped (early)
Does your paper address CONSORT subitem 14b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

The trial ended when sufficient participants had been recruited and been through study procedures.

15) A table showing baseline demographic and clinical characteristics for each group
NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

Does your paper address CONSORT subitem 15? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. Table 2 shows the demographic data and baseline characteristics of the sample by groups.

15-i) Report demographics associated with digital divide issues
In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

subitem not at all important 1 2 3 4 5 essential

Does your paper address subitem 15-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not known. No digital divide issues

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

16-i) Report multiple “denominators” and provide definitions
Report multiple “denominators” and provide definitions: Report N's (and effect sizes) “across a range of study participation [and use] thresholds” [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants “used” the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define “use” of the intervention.

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 16-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes.Is included in the section Results (table 3,4,6 to 8).
### 16-ii) Primary analysis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i).

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important | | | | | essential |

Borrar selección

---

**Does your paper address subitem 16-ii?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this* to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes.Is included in the section Results Primary analysis intent-to-treat (table 3 to 5), secondary analyses (table 6,7).

---

**17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)**

**Does your paper address CONSORT subitem 17a? * **

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this* to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Effect size and significance reported for relevant outcomes. eg...."Additionally, the variations between the different phases were assessed by means of the percentage change rescaled with log base 2"....(for further information see RESULTS section in ms).
17a-i) Presentation of process outcomes such as metrics of use and intensity of use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as “average session length”. These must be accompanied by a technical description how a metric like a “session” is defined (e.g., timeout after idle time) [1] (report under item 6a).

1 2 3 4 5
subitem not at all important ○ ○ ● ○ ○ essential

Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

This study did not use metrics of use and intensity as it was not relevant to the conditions analysed.

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. Control group used for this study. Effect sizes reported for relevant outcomes. (for further information see RESULTS in ms).
18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes, "A linear mixed effects model [56,57] was subsequently used to assess changes over time for the repeated measurements of the pain questionnaire scores at three time points between the control group and treatment group. Linear mixed effects models account for variability between subjects and variability between repeated measurements in the same subject simultaneously. To obtain different trajectories for each group (experimental vs. control) over time, we included the intercept and slope effect as random effects; and time, group and the interaction term (group × time) as fixed effects. The variance-covariance structure was fixed to an unstructured matrix and the random effects and error terms were assumed to have a normal distribution".

18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ ☑ essential

Borrar selección
19) All important harms or unintended effects in each group
(for specific guidance see CONSORT for harms)

Does your paper address subitem 18-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No subgroup analysis was used.

19) All important harms or unintended effects in each group
(for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No harms or unintended effects.

19-i) Include privacy breaches, technical problems
Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

1 2 3 4 5
subitem not at all important

essential
Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

No privacy breaches. Technical problems were minimal and were restricted to a user having to repeat intervention.

19-ii) Include qualitative feedback from participants or observations from staff/researchers

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

1 2 3 4 5

subitem not at all important ☐ ☐ ☐ ☐ ☐ essential

Borrar selección
Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Firstly, we developed a multimodal program involving a variety of therapeutic activities that could be standardized and used in the future for other patients with chronic pain. An encouraging finding in this line was that the benefits of the treatment were largely maintained at follow-up, which may suggest that these interventions lead to the acquisition of skills that result in behavioral change, at least in the medium term. Secondly, ICTs were used in combination with pharmacological and non-pharmacological therapeutic treatments in the outpatient setting to evaluate their impact on pain catastrophizing, pain acceptance and quality of life. Thirdly, the fact that patients did the programmed activities in their natural environment is likely to promote self-efficacy, thus supporting the importance of the self-management component in interventions of this type[26].
Does your paper address subitem 22-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. The results of the study clearly show that the main variable, catastrophizing, had a significant positive effect on the intervention group compared to the control group after the intervention and at 3 months follow-up. This could be due to changes in cognition or maladaptive behavior that modified erroneous beliefs and decreased catastrophic thoughts. It should be noted that previous research has considered the beneficial effect of multimodal treatments in decreasing catastrophizing and fear. Thus, these results would be in accordance with the more pronounced effect found in the group that received the treatment[57].

These results are also in line with the findings of studies on the effects of monotherapies using ACT[58] and mindfulness [59], physical activity, pharmacological therapy and the health assets approach. The analysis of the results showed that the intervention group improved in catastrophizing, psychological flexibility, movement avoidance, pain interference in daily life and pain intensity and quality of life.[32,60-64]

22-ii) Highlight unanswered new questions, suggest future research

Highlight unanswered new questions, suggest future research.

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ ● essential

Borrar selección

https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_Oim...en_US&formkey=dGlKd2Z2Q1INSGQ0THIazM5MS1aWWc6MA&rm=full
Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"In future research, more attention should also be given to the participants’ gender as this could have affected our findings. It is well known that gender is strongly related to access to care and treatment response and that while many patients who suffer pain from are women, many stigmas are associated with pain in men. Therefore, it is important that we gain a better understanding of the role of gender in healthcare access, as well as gender biases in diagnoses, patient-professional interactions and treatment. Further lines of research could improve the efficacy of multimodal chronic pain interventions based on new technologies, such as the refinement of treatments, the identification of moderating factors that might influence psychosocial variables and their association with treatment adherence. To evaluate which groups of patients are more competent to self-manage a technology-based multimodal intervention would have been ideal. In the same vein, it is also worth mentioning that in our study we have not specifically assessed satisfaction in relation to the use of technologies and this could be a promising line for future research."

---

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

| Subitem | 1 | 2 | 3 | 4 | 5 |
|---------|---|---|---|---|---|
| Not at all important | | | | | |}

essential
Does your paper address subitem 20-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes.“The low response rate of the self-reported questionnaires sent via email”. we used a "multimodal therapy", "we cannot really know the effect of each individual intervention on the outcomes"
"The electronic records on participants’ access to and completion of the activities were not analyzed, we do know that 85% completed the intervention program”.

21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ ○ essential

Borrar selección
Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"A large number of studies have been conducted on ICT-based interventions to promote self-management in people with chronic pain [77-79], and there is evidence of high ICT acceptance and satisfaction[74, 75]. Indeed, because technologies can assist and support people in their daily lives and at any time of the day[33], smartphones have become a very effective healthcare tool. In our smartphone app, we have selected evidence-based activities to address the various dimensions of chronic pain. The activities are easily reproducible in many environments and healthcare fields and can serve as complementary therapies for the comprehensive treatment of people with persistent pain. Nonetheless, it should be noted that self-management for pain management is only effective when implemented from a multidisciplinary approach, as treatment response is individual and there is no single approach that is beneficial for all patients with chronic pain. Therefore, for smartphone-based applications to be successful in promoting the self-management of chronic pain, we believe they should include self-monitoring, goal setting, skills training, social support and educational components. Moreover, many of these applications appear to have been developed without the involvement of patients and health care professionals and, to the best our knowledge, few have been tested in randomized trials to evaluate their impact on health."

21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important | ☐ | ☐ | ☑ | ☐ | ☐ | essential |

Borrar selección
Does your paper address subitem 21-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A - As this is novel research in social, there is no 'routine application'.

OTHER INFORMATION

23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Trial Registration: ClinicalTrial.gov (NCT04509154)
https://clinicaltrials.gov/ct2/show/NCT04509154

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? *
Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Can contact researchers for full trial protocol.
25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. This study has been funded by the Regional Ministry of Health by Resolution of 18 May 2017 with the collaboration of the Biomedical Research Foundation of Cordoba (IMIBIC).

X27) Conflicts of Interest (not a CONSORT item)

X27-i) State the relation of the study team towards the system being evaluated
In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

1 2 3 4 5

subitem not at all important ☐ ☐ ☐ ☐ ☑ essential

Does your paper address subitem X27-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The authors declare no conflicts of interest.
About the CONSORT EHEALTH checklist

As a result of using this checklist, did you make changes in your manuscript? *

- yes, major changes
- yes, minor changes
- no

What were the most important changes you made as a result of using this checklist?

Details of the methods were added

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript *

More than 20 hours INCLUDING making changes in the manuscript

As a result of using this checklist, do you think your manuscript has improved? *

- yes
- no
- Otro:
Would you like to become involved in the CONSORT EHEALTH group?

This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document

- yes
- no
- Otro:

Any other comments or questions on CONSORT EHEALTH

Tu respuesta

STOP - Save this form as PDF before you click submit

To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit!

Click submit so we have your answers in our database!

Enviar

Nunca envíes contraseñas a través de Formularios de Google.

Este contenido no ha sido creado ni aprobado por Google. Notificar uso inadecuado - Términos del Servicio - Política de Privacidad

Google Formularios

https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_Oim...en_US&formkey=dGIlKd2Z2Q1lINSQ0THtfaZMS1aWWc6MA&rm=full